Novel combination therapies targeting the ribosome to treat prostate cancer

  • Furic, Luc (Primary Chief Investigator (PCI))
  • Daly, Roger (Chief Investigator (CI))
  • Hannan, Ross (Chief Investigator (CI))
  • Risbridger, Gail (Chief Investigator (CI))
  • Pearson, Richard D. (Partner Investigator (PI))
  • Sandhu, Shahneen (Partner Investigator (PI))

Project: Research

StatusFinished
Effective start/end date1/05/15 → 30/04/18

Funding

  • Cancer Australia: AUD255,000.00
View all
View less

Related content

Research Output

Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription

Research output: Contribution to journal › Article › Research › peer-review

mTOR-sensitive translation: Cleared fog reveals more trees

Research output: Contribution to journal › Review Article › Research › peer-review

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy

Research output: Contribution to journal › Article › Research › peer-review